SUANFARMA Group

About SUANFARMA Group

SUANFARMA founded in 1993, is a B2B life science partner specialized in the development, production and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries. Our APIs facilities comply with the highest existing regulations in the pharmaceutical industry and a consolidated and strong commercial network with 12 local offices placed strategically around the world, SUANFARMA provides its services to more than 3.000 active customers in over 70 countries.

Certifications
  • ES
  • 2015
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
Distributor/Import Export
Manufacturer/Innovator
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Germany
1-3 November 2022

Products from SUANFARMA Group (15)

  • ANASTROZOLE
  • BISOPROLOL

    Product BISOPROLOL

    ANTIHYPERTENSIVE
  • CLOBUTINOL HCL

    Product CLOBUTINOL HCL

    ANTITUSSIVES. COUGH SUPPRESSANT
  • ENOXAPARINE SODIUM
  • RIVAROXABAN

    Product RIVAROXABAN

    ANTICOAGULANTS
  • IMATINIB MESYLATE
  • GABAPENTIN

    Product GABAPENTIN

    ANTIEPILEPTIC
  • FIROCOXIB

    Product FIROCOXIB

    ANALGESIC (VETERINARY)
  • TULATHROMYCIN

    Product TULATHROMYCIN

    ANTIBIOTIC (VETERINARY)
  • QUETIAPINE FUMARATE
  • ALTRENOGEST

    Product ALTRENOGEST

    Veterinary use. It is a synthetic progestogen (sex hormone), programmer and synchronizer of the estrous cycle in swine and horses.
  • CHLORTHALIDONE

    Product CHLORTHALIDONE

    Human use. Diuretic used in the treatment of arterial hypertension and chronic stable heart failure. Diuretic and antihypertensive

SUANFARMA Group Resources (5)

  • Video SUANFARMA - CORPORATE VIDEO

    SUANFARMA was born in Spain in 1993 and is specialized in the development, production and commercialization of ingredients for the pharmaceutical, veterinary, and nutritional sectors. 

    During the last 5 years the company has achieved the highest growth in its history and has acquired 5 new companies in Spain, Portugal, Colombia and Italy, increasing significantly its industrial and development capacity. SUANFARMA Group is represented by over 650 people, with presence in over 70 countries.

    At SUANFARMA, we are committed to health and innovation. We develop new technologies and processes to offer innovative products, following the trends of the world of health and the needs of our customers. We cover both “super sales” molecules and niche molecules or specialized therapies, controlling the production process from the intermediate to the final product.
  • Video Corporate video Cipan Lisbon

    Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history

    Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO).

  • Video SUANNUTRA

    SUANNUTRA is a reference company in the nutraceutical ingredients sector, supporting customers by satisfying their supply needs and accompanying them in their commercial success. We are present from research and development to market launch. We offer both essential ingredients and the most select compounds, with proven scientific evidence.
  • Video CIPAN

    Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history

    Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO).

  • Video CIPAN

    Founded in 1960, Cipan is a company committed to health, and this has been demonstrated in its more than 50-year history

    Cipan has developed, either through its own investment or through CDO strategies, three generations of APIs derived from Tetracycline: Tetracycline, Minocycline, Lymecycline, Oxytetracycline, and other third-generation molecules that are currently in commercial phase (CMO) or development (CDO).